161 related articles for article (PubMed ID: 35953766)
1. Assessing the impact of MRI based diagnostics on pre-treatment disease classification and prognostic model performance in men diagnosed with new prostate cancer from an unscreened population.
Lophatananon A; Byrne MHV; Barrett T; Warren A; Muir K; Dokubo I; Georgiades F; Sheba M; Bibby L; Gnanapragasam VJ
BMC Cancer; 2022 Aug; 22(1):878. PubMed ID: 35953766
[TBL] [Abstract][Full Text] [Related]
2. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study.
Gnanapragasam VJ; Bratt O; Muir K; Lee LS; Huang HH; Stattin P; Lophatananon A
BMC Med; 2018 Feb; 16(1):31. PubMed ID: 29490658
[TBL] [Abstract][Full Text] [Related]
3. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
4. Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database.
Lee C; Light A; Alaa A; Thurtle D; van der Schaar M; Gnanapragasam VJ
Lancet Digit Health; 2021 Mar; 3(3):e158-e165. PubMed ID: 33549512
[TBL] [Abstract][Full Text] [Related]
5. Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery.
Ploussard G; Manceau C; Beauval JB; Lesourd M; Almeras C; Gautier JR; Loison G; Salin A; Soulié M; Tollon C; Malavaud B; Roumiguié M
World J Urol; 2020 Oct; 38(10):2493-2500. PubMed ID: 31838560
[TBL] [Abstract][Full Text] [Related]
6. Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study.
Zelic R; Garmo H; Zugna D; Stattin P; Richiardi L; Akre O; Pettersson A
Eur Urol; 2020 Feb; 77(2):180-188. PubMed ID: 31606332
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Magnetic Resonance Imaging-directed Biopsy Strategies for Changing the Paradigm of Prostate Cancer Diagnosis.
Schoots IG; Padhani AR; Rouvière O; Barentsz JO; Richenberg J
Eur Urol Oncol; 2020 Feb; 3(1):32-41. PubMed ID: 31706946
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
9. Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0).
Ettala O; Jambor I; Montoya Perez I; Seppänen M; Kaipia A; Seikkula H; Syvänen KT; Taimen P; Verho J; Steiner A; Saunavaara J; Saukko E; Löyttyniemi E; Sjoberg DD; Vickers A; Aronen H; Boström P
BMJ Open; 2022 Apr; 12(4):e053118. PubMed ID: 35428621
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation.
Parry MG; Cowling TE; Sujenthiran A; Nossiter J; Berry B; Cathcart P; Aggarwal A; Payne H; van der Meulen J; Clarke NW; Gnanapragasam VJ
BMC Med; 2020 May; 18(1):114. PubMed ID: 32460859
[TBL] [Abstract][Full Text] [Related]
13. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
Grönberg H; Eklund M; Picker W; Aly M; Jäderling F; Adolfsson J; Landquist M; Haug ES; Ström P; Carlsson S; Nordström T
Eur Urol; 2018 Dec; 74(6):722-728. PubMed ID: 30001824
[TBL] [Abstract][Full Text] [Related]
14. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
15. Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naïve men: a large cohort validation study.
Bittencourt LK; Guricova K; Zucker I; Durieux JC; Schoots IG
Eur Radiol; 2022 Apr; 32(4):2330-2339. PubMed ID: 35028750
[TBL] [Abstract][Full Text] [Related]
16. Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study.
Klemann N; Røder MA; Helgstrand JT; Brasso K; Toft BG; Vainer B; Iversen P
Lancet Oncol; 2017 Feb; 18(2):221-229. PubMed ID: 28094199
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study.
Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Winther MD; Jakobsen H; Thomsen HS
JAMA Netw Open; 2018 Jun; 1(2):e180219. PubMed ID: 30646066
[TBL] [Abstract][Full Text] [Related]
19. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis.
Drost FH; Osses D; Nieboer D; Bangma CH; Steyerberg EW; Roobol MJ; Schoots IG
Eur Urol; 2020 Jan; 77(1):78-94. PubMed ID: 31326219
[TBL] [Abstract][Full Text] [Related]
20. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.
Gandaglia G; Ploussard G; Valerio M; Mattei A; Fiori C; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Moschini M; Zamboni S; Rakauskas A; Tian Z; Karakiewicz PI; De Cobelli F; Porpiglia F; Montorsi F; Briganti A
Eur Urol; 2020 Jun; 77(6):733-741. PubMed ID: 31547938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
